Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2860001 | 0.88 | ADORA2A (0.42) | ALDH1A1LMNANPSR1ABCG2ADORA2A | |
| SCHEMBL2469222 | 0.83 | ADORA2A (0.38) | ALDH1A1LMNANPSR1ABCG2ADORA2A | |
| SCHEMBL30084116 | 0.81 | PTGER1 (0.38) | ALDH1A1ADORA2AADORA1TDP1MAPK1 | |
| SCHEMBL173515 | 0.81 | PTGER1 (0.38) | ALDH1A1ADORA2AADORA1TDP1MAPK1 | |
| SCHEMBL13854481 | 0.81 | ALDH1A1 (0.44) | ALDH1A1LMNANPSR1ABCG2ADORA2A | |
| SCHEMBL2465175 | 0.81 | L3MBTL1 (0.54) | ALDH1A1LMNANPSR1ABCG2MEN1 | |
| SCHEMBL27811931 | 0.78 | MEN1 (0.37) | ALDH1A1NPC1MEN1KMT2ARAB9A | |
| SCHEMBL2280858 | 0.77 | CNR1 (0.35) | ADORA2AMAPK1TDO2 | |
| SCHEMBL2468163 | 0.77 | MERTK (0.34) | ADORA2AADORA1MAPK1MAPK13MAPK12 | |
| SCHEMBL3152058 | 0.76 | ALDH1A1 (0.33) | ALDH1A1LMNANPSR1ABCG2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| EP-1966151-B1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORP (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| EP-1966151-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| WO-2007070398-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | ALDH1A1 277/4885LMNA 4516/4885NPSR1 3152/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | ALDH1A1 342/4885LMNA 4536/4885NPSR1 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.